NS Pharma, Inc.
Arthur Mate has extensive experience in quality assurance within the pharmaceutical industry, currently serving as the Senior Director and U.S. Head of Quality Assurance at NS Pharma, Inc. since October 2019. Prior to this role, Arthur held positions at Celgene as Associate Director of Clinical Quality Assurance and Director of Quality Assurance, contributing expertise in compliance, audits, and process improvement from April 2007 to October 2019. At Eisai Medical Research, Arthur was responsible for the U.S. implementation of Documentum in a global system from April 2000 to April 2007. Arthur began a career at Roche in 1985, focusing on GLP auditing until March 2000. Educational credentials include an MBA in Business from Montclair State University and a degree in Medical Technology from UMDNJ.
This person is not in the org chart
This person is not in any teams
NS Pharma, Inc.
2 followers
NS Pharma, Inc. (NSP) located in Paramus New Jersey is a subsidiary of Nippon Shinyaku Co., Ltd. Founded in 1999 in the United States, NSP is engaged in clinical studies and partnering with global pharmaceutical companies, venture companies and research institutes. NSP serves as a contact point for connecting Japan/Asia and the world, developing drug candidates invented in Japan and out-license them to the world. From the world to Japan/Asia, NSP in-license promising drug candidates to the Japanese/Asian Markets. In coordination with parent company, Nippon Shinyaku, Co., Ltd., NSP will first and foremost develop and supply safe and highly effective pharmaceuticals through clinical studies. NSP aims to be an indispensable entity in the healthcare industry in line with the guidelines for action “Challenge”, “Speed”, and “Investigation”.